News

FB-101, an experimental oral therapy that 1ST Biotherapeutics is developing as a treatment for Parkinson’s disease, was well-tolerated in the first part of a Phase 1 clinical trial in healthy volunteers, the company announced. In the trial of (NCT04165837), which is being conducted in Baltimore,  24 adults…

REM sleep behavior disorder (RBD) and autonomic dysfunction (dysautonomia), two types of nonmotor Parkinson’s disease symptoms, were significant predictors of anxiety in Parkinson’s patients over a three-year study. More than half (57%) of patients in in the study met the clinical criteria for anxiety at some point, underscoring its…

A transplant of stem cell-derived nerve cells engineered to produce a signaling factor that promotes nerve health was shown to lessen motor deficits and increase dopamine activity in a rat model of Parkinson’s disease. The signaling factor, BDNF, is seen as a potentially effective treatment for Parkinson’s. While…

Differing natural sleeping schedules, known as a person’s chronotype, do not associate with daytime sleepiness in people with Parkinson’s disease, a study reported. Rather, daytime sleepiness related most to the type of dopamine therapy that patients used. But no significant differences were evident between morning or evening chronotypes, or those…

Two small molecules in the pipeline of Lucy Therapeutics helped nerve cells (neurons) keep their mitochondria healthier and reduced the levels of  alpha-synuclein, a protein that builds as toxic clumps in the brain of people with Parkinson’s disease. These molecules, called LucyTx-1209 and LucyTx-1212, also were seen…

Enterin has teamed with Parkinson’s UK to launch a Phase 2 trial evaluating the ability of ENT-01, its investigational compound, to lessen Parkinson’s disease-associated dementia. The clinical trial will be led by Parkinson’s Virtual Biotech, the treatment development arm of Parkinson’s UK, and will be conducted at…

A new strategy that combines online cognitive therapeutic games with a noninvasive brain stimulation technique – called COGNISANT – may help boost short-term memory in older people, according to a new study. The findings may prove important for people with Parkinson’s disease who often experience a decline in short-term,…

Researchers have developed a software that can accurately identify people with Parkinson’s disease or multiple sclerosis (MS) from healthy controls based solely on their gait. The software, which analyzes gait video data collected at patients’ homes using simple digital cameras, may provide an inexpensive tool to identify and…

Muna Therapeutics has received a $4.9 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance  development of its first-in-class small molecules used to halt neuroinflammation and restore nerve cell function in people with Parkinson’s disease. The grant will fund preclinical research into small molecules…

Two clinically-proven speech therapy programs tailored to Parkinson’s disease patients, SPEAK OUT! and The LOUD Crowd, are now available at the Hackensack Meridian Johnson Rehabilitation Institute at Ocean University Medical Center, New Jersey. Both programs, developed by the nonprofit Parkinson Voice Project, are designed to help patients “speak…